We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Padcev Gains FDA Priority Reviews for Bladder Cancer Indication
Padcev Gains FDA Priority Reviews for Bladder Cancer Indication
The FDA has granted priority reviews for two supplemental Biologics License Applications (sBLAs) by Seagen and Astellas Pharma for Padcev, their antibody-drug conjugate therapy for treating bladder cancer.